Related Experiment Video
Updated: Oct 8, 2026

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform
Published on: November 9, 2017
Beyond correlation: Intraclass correlation and bland-altman analysis reveal poor absolute agreement across multiplex
Olfa Khalfallah1, Cynthia Le Mouroux1, Narjis Kraimi1
1Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, INSERM, Université Côte d'Azur, 660 Route Des Lucioles, 06560 Valbonne, France.
Abstract:
Cross-platform comparisons of serum cytokine immunoassays have often focused on rank correlation, but the extent of absolute agreement and systematic bias between platforms remains insufficiently characterized. Few independent head-to-head evaluations have compared multiple immunoassay platforms on the same clinical samples using overlapping cytokines. Here, serum samples from 48 adult participants were analyzed in parallel for seven cytokines (IL-6, IL-7, IL-8, IL-10, IL-15, TNF-α, IFN-γ), four chemokines (CCL2, CCL3, CCL4, CXCL10), and one growth factor (VEGF-A) using three multiplex platforms: OLINK proximity extension assay-based, LUMINEX bead-based, and V-PLEX electrochemiluminescence-based immunoassays. LLOQs, absolute concentrations, rank correlations, ICCs, and Bland-Altman biases were compared between platforms. Absolute serum cytokine concentrations differed by up to two orders of magnitude. Correlations between OLINK and V-PLEX were generally strong, whereas correlations involving LUMINEX were often weak or non-significant. ICCs were poor (<0.5) for most analytes and platform pairs, with IL-8 as a notable exception. Bland-Altman analyses on log-transformed concentrations revealed large, analyte-specific multiplicative biases and wide ratio-scale limits of agreement, indicating poor absolute agreement. These findings show that OLINK, LUMINEX, and V-PLEX measurements are not interchangeable at the level of absolute concentrations and underscore key analytical limitations that currently hinder the broad adoption of cytokine immunoassays, particularly multiplex panels, as regulator-approved tests.

